

CITATION REPORT

List of articles citing

Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides

DOI: 10.1016/j.lpm.2013.08.003
Presse Medicale, 2013, 42, 1317-30.

Source: <https://exaly.com/paper-pdf/55094344/citation-report.pdf>

Version: 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
57	Vascularites associées aux anticorps anticytoplasme des polynucléaires neutrophiles : nouveaux traitements. <i>Reanimation: Journal De La Societe De Reanimation De Langue Francaise</i> , 2014 , 23, 659-665		
56	Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis?. <i>Current Opinion in Rheumatology</i> , 2014 , 26, 292-8	5.3	3
55	Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients. <i>Journal of Autoimmunity</i> , 2014 , 50, 135-41	15.5	57
54	Rapidly progressive crescentic glomerulonephritis: Early treatment is a must. <i>Autoimmunity Reviews</i> , 2014 , 13, 723-9	13.6	75
53	Single-dose rituximab for remission induction and maintenance therapy in ANCA-associated vasculitis: a retrospective analysis of 17 patients. <i>Scandinavian Journal of Rheumatology</i> , 2014 , 43, 519-23	1.9	12
52	Treatment of severe and/or refractory ANCA-associated vasculitis. <i>Current Rheumatology Reports</i> , 2014 , 16, 430	4.9	8
51	Pituitary involvement in granulomatosis with polyangiitis: report of 9 patients and review of the literature. <i>Medicine (United States)</i> , 2015 , 94, e748	1.8	47
50	Biologics in vasculitides: Where do we stand, where do we go from now?. <i>Presse Medicale</i> , 2015 , 44, e231-9	1.9	4
49	Outcomes of patients admitted to intensive care units for acute manifestation of small-vessel vasculitis: a multicenter, retrospective study. <i>Critical Care</i> , 2016 , 20, 27	10.8	21
48	CanVasc recommendations for the management of antineutrophil cytoplasm antibody (ANCA)-associated vasculitides - Executive summary. <i>Canadian Journal of Kidney Health and Disease</i> , 2015 , 2, 43	2.3	9
47	Treatment of granulomatosis with polyangiitis (Wegener's). <i>Expert Review of Clinical Immunology</i> , 2015 , 11, 339-48	5.1	11
46	Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. <i>Autoimmunity Reviews</i> , 2015 , 14, 304-13	13.6	76
45	Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 1683-702	4	3
44	Biological drugs in ANCA-associated vasculitis. <i>International Immunopharmacology</i> , 2015 , 27, 209-12	5.8	14
43	[Alveolar hemorrhage]. <i>Revue Des Maladies Respiratoires</i> , 2015 , 32, 394-412	0	6
42	[Biologics in uveitis]. <i>Revue De Medecine Interne</i> , 2015 , 36, 107-16	0.1	6
41	Rituximab as Maintenance Therapy for ANCA Associated Vasculitis: How, When and Why?. <i>Reumatologia Clínica (English Edition)</i> , 2016 , 12, 39-46	0.1	

40	Scleroderma renal crisis and renal involvement in systemic sclerosis. <i>Nature Reviews Nephrology</i> , 2016 , 12, 678-691	14.9	67
39	Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease. <i>CKJ: Clinical Kidney Journal</i> , 2017 , 10, 461-469	4.5	26
38	Gut and Liver in Vasculitic Disorders. <i>Digestive Diseases</i> , 2016 , 34, 546-51	3.2	
37	New therapeutic approaches for ANCA-associated vasculitides. <i>Presse Medicale</i> , 2016 , 45, e171-8	2.2	1
36	[Pneumocystosis in non-HIV-infected immunocompromised patients]. <i>Revue De Medecine Interne</i> , 2016 , 37, 327-36	0.1	9
35	Therapeutic immunomodulation in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Joint Bone Spine</i> , 2016 , 83, 7-10	2.9	0
34	Immunomodulation thérapeutique dans la granulomatose éosinophilique avec polyangéite (Churg-Strauss). <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2016 , 83, 7-11	0.1	
33	Rituximab as maintenance therapy for ANCA associated vasculitis: how, when and why?. <i>Reumatologia Clínica</i> , 2016 , 12, 39-46	0.9	4
32	CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitides. <i>Journal of Rheumatology</i> , 2016 , 43, 97-120	4.1	47
31	Testing for antineutrophil cytoplasmic antibodies (ANCA) in patients with systemic vasculitides and other diseases. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, e23	2.4	4
30	Perspectives de traitement par biomédicaments dans la granulomatose éosinophilique avec polyangéite (Churg-Strauss). <i>Revue Du Rhumatisme Monographies</i> , 2017 , 84, 256-261	0	1
29	Patients with ANCA-associated vasculitis admitted to the intensive care unit with acute vasculitis manifestations: a retrospective and comparative multicentric study. <i>Annals of Intensive Care</i> , 2017 , 7, 39	8.9	21
28	Recomendações da Sociedade Brasileira de Reumatologia para a terapia de indução para vasculite associada a ANCA. <i>Revista Brasileira De Reumatologia</i> , 2017 , 57, 484-496		7
27	Recommendations of the Brazilian Society of Rheumatology for the induction therapy of ANCA-associated vasculitis. <i>Revista Brasileira De Reumatologia</i> , 2017 , 57 Suppl 2, 484-496		8
26	[Current guidelines on ANCA-associated vasculitides : Common features and differences]. <i>Zeitschrift Fur Rheumatologie</i> , 2017 , 76, 133-142	1.9	4
25	ANCA-Associated Vasculitis. 2017 , 459-502		1
24	Clinical practice variation and need for pediatric-specific treatment guidelines among rheumatologists caring for children with ANCA-associated vasculitis: an international clinician survey. <i>Pediatric Rheumatology</i> , 2017 , 15, 61	3.5	11
23	Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1143-1149	2.4	123

22	Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders. <i>Autoimmunity Reviews</i> , 2018 , 17, 115-124	13.6	35
21	Monoclonal Anti-CD20 (B-Cell) Antibody and Autoimmune Diseases. 2018 , 343-363		
20	Therapeutic plasma exchange - A brief review of indications, urgency, schedule, and technical aspects. <i>Transfusion and Apheresis Science</i> , 2019 , 58, 237-246	2.4	12
19	Treatment of ANCA-associated vasculitides: Certainties and controversies. <i>Nephrologie Et Therapeutique</i> , 2019 , 15 Suppl 1, S7-S12	0.6	1
18	Stratégies d'immunothérapie ciblée au cours des vascularites associées aux ANCA. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2019 , 86, 33-38	0.1	
17	Targeted immunotherapy strategies in ANCA-associated vasculitis. <i>Joint Bone Spine</i> , 2019 , 86, 321-326	2.9	6
16	Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort. <i>Acta Clinica Belgica</i> , 2020 , 75, 163-169	1.8	0
15	Eosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the disease. <i>Expert Review of Clinical Immunology</i> , 2020 , 16, 51-61	5.1	8
14	Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis. <i>Autoimmunity Reviews</i> , 2020 , 19, 102505	13.6	8
13	ANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission induction and maintenance. <i>Presse Medicale</i> , 2020 , 49, 104031	2.2	6
12	ANCA associated vasculitis. <i>European Journal of Internal Medicine</i> , 2020 , 74, 18-28	3.9	13
11	French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides). <i>Orphanet Journal of Rare Diseases</i> , 2020 , 15, 351	4.2	13
10	Hémorragies intra-alvéolaires. <i>Medecine Intensive Reanimation</i> , 2018 , 27, 331-343	0.1	1
9	Classification, diagnosis and treatment of ANCA-associated vasculitis. <i>World Journal of Rheumatology</i> , 2015 , 5, 36	0.5	4
8	Treatment of ANCA-Associated Vasculitides. 2016 , 425-431		
7	PULMONARY-RENAL SYNDROME: DIFFICULTIES OF DIFFERENTIAL DIAGNOSIS. <i>Klinicist</i> , 2018 , 12, 43-50	0.3	
6	Granulomatosis with Polyangiitis. <i>Rare Diseases of the Immune System</i> , 2020 , 97-129	0.2	0
5	Microscopic polyangiitis and granulomatosis with polyangiitis. 2019 , 153-172		0

4	Early infectious risk in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis according to remission-induction therapy.. <i>Scandinavian Journal of Rheumatology</i> , 2022 , 1-13	1.9
3	The Pathogenesis and Diagnosis of <i>Pneumocystis jiroveci</i> Pneumonia. 2022 , 8, 1167	○
2	Health care costs and utilization prior to diagnosis of antineutrophil cytoplasmic antibody vasculitis in Medicare beneficiaries. 2022 , 28, 1292-1303	○
1	Current Treatment of ANCA Vasculitis.	○